As immune cell aggregates, TLSs have been validated as immune predictors of the response to cancer immunotherapy, likely due to the induction of carcinoma‐associated fibroblasts, antigen presentation by dendritic cells, and anti‐tumor activities of CD8+ T and B cells within TLSs.14, 17, 27, 28. The gene discussed is CD8A; the disease is carcinoma.